MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

MDV3800-06 TALAPRO-1

Protocol Title

A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men with DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer who Previously Received Taxane-Based Chemotherapy and Progressed On at Least 1 Novel Hormonal Agent (Enzalutamide And/Or Abiraterone Acetate/Prednisone)

MK-1308-001

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumours

MK-3475-119

Keynote-119

MK-3475-564

Keynote-564

MK-3475-716

Keynote-716

MK-3475-B61

Keynote-B61

MK-7684-001

Keyvibe-001

MO28047 PERUSE

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy Per Physician'S Choice for Metastatic Triple Negative Breast Cancer (MTNBC)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy

Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma: a Randomized, Double-Blind Phase 3 Study

A Phase 2, Single-Arm, Open-Label Clinical Trial of Pembrolizumab plus Lenvatinib in Participants with First-Line Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma (NCCRCC) (Keynote-B61)

A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumours

A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination with Trastuzumab and a Taxane in First Line Treatment of Patients with HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer

MO29983 SAUL

An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

MS200647-0055 INTR@

PID BTC-055

A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Gemcitabine plus Cisplatin with and Without M7824 as a First-Line Treatment of Biliary Tract Cancer